Never Stop Bioteching

Webinar: Oncology drug development 

Identifying regulator and payer evidence needs

The industry-wide focus on cancer has placed it at the forefront of regulatory, scientific, and clinical advances, from expedited mechanisms to biomarkers to adaptive trials. And the coronavirus pandemic has accelerated adoption of further innovations, such as decentralized clinical trials (DCTs) and real-world evidence (RWE), that regulators and payers are increasingly accepting. There will be no going back to a pre-COVID world.

To succeed, developers need to create cancer drugs that are both approvable and reimbursable. This requires a solid, integrated evidence strategy that accommodates the data to support the safety, quality and efficacy requirements of regulators, a coherent, data-driven value story for payers, and one that ultimately demonstrates how your new therapy is relevant to patients’ real lives.